Efficacy and Safety of Zavegepant Nasal Spray for the Acute Treatment of Migraine: Results of a Phase 3 Double-Blind, Randomized, Placebo Controlled Trial

被引：0

作者：

Mullin, K. ^{[1
]}

Croop, R. ^{[2
]}

Pavlovic, J. ^{[3
]}

Mosher, L. ^{[2
]}

Smith, T. ^{[4
]}

Madonia, J. ^{[2
]}

Lovegren, M. ^{[2
]}

Coric, V. ^{[2
]}

Lipton, R. ^{[3
]}

机构：

[1] New England Inst Neurol & Headache, Stamford, CT USA

[2] Biohaven Pharmaceut, New Haven, CT USA

[3] Albert Einstein Coll Med, Bronx, NY 10467 USA

[4] Study Metrix Res, St Peters, MO USA

来源：

JOURNAL OF HEADACHE AND PAIN | 2022年 / 23卷 / SUPPL 1期

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P136a

引用

页数：2

共 50 条

[21] Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial
Detyniecki, Kamil
Van Ess, Peter J.
Sequeira, David J.
Wheless, James W.
Meng, Tze-Chiang
Pullman, William E.
EPILEPSIA, 2019, 60 (09) : 1797 - 1808
[22] Efficacy and Safety of Cinnarizine in the Prophylaxis of Migraine in Children: A Double-Blind Placebo-Controlled Randomized Trial
Ashrafi, Mahmoud Reza
Salehi, Soodeh
Malamiri, Reza Azizi
Heidari, Morteza
Hosseini, Seyed Ahmad
Samiei, Mahboubeh
Tavasoli, Ali Reza
Togha, Mansoureh
PEDIATRIC NEUROLOGY, 2014, 51 (04) : 503 - 508
[23] Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study
Takeshima, Takao
Sakai, Fumihiko
Hirata, Koichi
Imai, Noboru
Matsumori, Yasuhiko
Yoshida, Ryuji
Peng, Cheng
Cheng, Sunfa
Mikol, Daniel D.
HEADACHE, 2021, 61 (06): : 927 - 935
[24] Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3, Randomized, Double-blind, Placebo-controlled Trial
Jones, A.
O'Gorman, C.
Lipton, R. B.
Tepper, S. J.
Tabuteau, H.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 152 - 152
[25] Efficacy and Safety of AXS-07 (MoSEIC Meloxicam-Rizatriptan) for the Acute Treatment of Migraine: Results from the INTERCEPT Phase 3, Randomized, Double-blind, Placebo-controlled Trial
Jones, A.
O'Gorman, C.
Lipton, R. B.
Tepper, S. J.
Tabuteau, H.
JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 102 - 102
[26] Eletriptan for the acute treatment of migraine in adolescents: Results of a double-blind, placebo-controlled trial
Winner, Paul
Linder, Steven L.
Lipton, Richard B.
Almas, Mary
Parsons, Bruce
Pitman, Verne
HEADACHE, 2007, 47 (04): : 511 - 518
[27] Efficacy and safety of palmitoylethanolamide as an adjunctive treatment for acute mania: A randomized, double-blind, placebo-controlled trial
Abedini, Talieh
Hosseyni, Reyhaneh
Ghannadi, Farnaz
Moghaddam, Hossein Sanjari
Ardakani, Mohammad-Reza Khodaei
Talaei, Ali
Akhondzadeh, Shahin
PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2022, 76 (10) : 505 - 511
[28] Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial
Croop, Robert
Goadsby, Peter J.
Stock, David A.
Conway, Charles M.
Forshaw, Micaela
Stock, Elyse G.
Coric, Vladimir
Lipton, Richard B.
LANCET, 2019, 394 (10200): : 737 - 745
[29] Efficacy of Zavegepant Nasal Spray for the Acute Treatment of Migraine Based on Triptan Treatment Experience: Pooled Results From 2 Randomized, Placebo- Controlled Clinical Trials
Joshi, S.
Smith, T.
Pavlovic, J.
Mullin, K.
Croop, R.
Mosher, L.
Lovegren, M.
Forshaw, M.
Lipton, R.
HEADACHE, 2023, 63 : 137 - 138
[30] A Phase 2/3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Rimegepant for the Preventive Treatment of Migraine
Croop, R.
Lipton, R. B.
Kudrow, D.
Stock, D. A.
Kamen, L.
Conway, C. M.
Stock, E. G.
Coric, V.
Goadsby, P. J.
CEPHALALGIA, 2021, 41 (1_SUPPL) : 28 - 29

← 1 2 3 4 5 →